Opus Genetics CEO Buys 392k Shares, Signals Strong Confidence Ahead of Phase‑3
Opus Genetics CEO’s fresh $451k insider purchase signals confidence amid 340% annual gains and a pending Phase‑3 trial, boosting investor insight.
3 minutes to read
OPUS GENETICS INC